Impact of immune complex size and glycosylation on IgG binding to human FcγRs

Journal of Immunology

Volumn 190, Issue 8, 2013, Pages 4315-4323

  Lux, Anja ^a   Yu, Xiaojie ^b   Scanlan, Chris N ^b   Nimmerjahn, Falk ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD33 ANTIGEN; FC RECEPTOR; FC RECEPTOR IIA; FUCOSE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; N ACETYLGLUCOSAMINE;

ANIMAL CELL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL ACTIVATION; CONTROLLED STUDY; CYTOLYSIS; DEGLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RECEPTOR BINDING;

ALLELES; ANIMALS; ANTIGEN-ANTIBODY COMPLEX; BINDING SITES, ANTIBODY; CELL LINE; CHO CELLS; CRICETINAE; GLYCOSIDE HYDROLASES; GLYCOSYLATION; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; MICE; MUTATION; PEPTIDE-N4-(N-ACETYL-BETA-GLUCOSAMINYL) ASPARAGINE AMIDASE; RECEPTORS, IGG; RECOMBINANT PROTEINS;

EID: 84875998684     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200501     Document Type: Article

References (57)

1. Jefferis, R. 2007. Antibody therapeutics: isotype and glycoform selection. Expert Opin. Biol. Ther. 7: 1401-1413.
2. Reichert, J. M., C. J. Rosensweig, L. B. Faden, and M. C. Dewitz. 2005. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23: 1073-1078.
3. Glennie, M. J., and J. G. van de Winkel. 2003. Renaissance of cancer therapeutic antibodies. Drug Discov. Today 8: 503-510.
4. Hogarth, P. M. 2002. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr. Opin. Immunol. 14: 798-802.
5. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8: 34-47.
6. Takai, T. 2002. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2: 580-592.
7. Daëron, M., and R. Lesourne. 2006. Negative signaling in Fc receptor complexes. Adv. Immunol. 89: 39-86.
8. Nimmerjahn, F., and J. V. Ravetch. 2007. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 19: 239-245.
9. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6: 443-446.
10. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99: 754-758.
11. Weng, W. K., D. Czerwinski, J. Timmerman, F. J. Hsu, and R. Levy. 2004. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 22: 4717-4724.
12. Weng, W. K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21: 3940-3947.
13. Musolino, A., N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti, G. Missale, D. Laccabue, A. Zerbini, R. Camisa, G. Bisagni, et al. 2008. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26: 1789-1796.
14. Tak, P. P., and J. R. Kalden. 2011. Advances in rheumatology: new targeted therapeutics. Arthritis Res. Ther. 13(Suppl. 1): S5.
15. Steinman, R. M., D. Hawiger, and M. C. Nussenzweig. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21: 685-711.
16. Trumpfheller, C., M. P. Longhi, M. Caskey, J. Idoyaga, L. Bozzacco, T. Keler, S. J. Schlesinger, and R. M. Steinman. 2012. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J. Intern. Med. 271: 183-192.
17. Ghetie, V., and E. S. Ward. 2000. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu. Rev. Immunol. 18: 739-766.
18. Roopenian, D. C., and S. Akilesh. 2007. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7: 715-725.
19. Baudino, L., Y. Shinohara, F. Nimmerjahn, J. Furukawa, M. Nakata, E. Martínez-Soria, F. Petry, J. V. Ravetch, S. Nishimura, and S. Izui. 2008. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J. Immunol. 181: 6664-6669.
20. Shields, R. L., A. K. Namenuk, K. Hong, Y. G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, et al. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276: 6591-6604.
21. Nimmerjahn, F., and J. V. Ravetch. 2006. Fcgamma receptors: old friends and new family members. Immunity 24: 19-28.
22. Bruhns, P., B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daëron. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725.
23. Nimmerjahn, F., P. Bruhns, K. Horiuchi, and J. V. Ravetch. 2005. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23: 41-51.
24. Küster, B., S. F. Wheeler, A. P. Hunter, R. A. Dwek, and D. J. Harvey. 1997. Sequencing of N-linked oligosaccharides directly from protein gels: in-gel deglycosylation followed by matrix-assisted laser desorption/ionization mass spectrometry and normal-phase high-performance liquid chromatography. Anal. Biochem. 250: 82-101.
25. Creighton, W. D., P. H. Lambert, and P. A. Miescher. 1973. Detection of antibodies and soluble antigen-antibody complexes by precipitation with polyethylene glycol. J. Immunol. 111: 1219-1227.
26. Albert, H., M. Collin, D. Dudziak, J. V. Ravetch, and F. Nimmerjahn. 2008. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc. Natl. Acad. Sci. USA 105: 15005-15009.
27. Nimmerjahn, F., and J. V. Ravetch. 2008. Analyzing antibody-Fc-receptor interactions. Methods Mol. Biol. 415: 151-162.
28. Karlsson, M. C., S. Wernersson, T. Diaz de Ståhl, S. Gustavsson, and B. Heyman. 1999. Efficient IgG-mediated suppression of primary antibody responses in Fcgamma receptor-deficient mice. Proc. Natl. Acad. Sci. USA 96: 2244-2249.
29. Kaneko, Y., F. Nimmerjahn, and J. V. Ravetch. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.
30. Arnold, J. N., M. R. Wormald, R. B. Sim, P. M. Rudd, and R. A. Dwek. 2007. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25: 21-50.
31. Lund, J., N. Takahashi, J. D. Pound, M. Goodall, and R. Jefferis. 1996. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J. Immunol. 157: 4963-4969.
32. Shibata-Koyama, M., S. Iida, A. Okazaki, K. Mori, K. Kitajima-Miyama, S. Saitou, S. Kakita, Y. Kanda, K. Shitara, K. Kato, and M. Satoh. 2009. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation. Glycobiology 19: 126-134.
33. Zeck, A., G. Pohlentz, T. Schlothauer, J. Peter-Katalinic, and J. T. Regula. 2011. Cell type-specific and site directed N-glycosylation pattern of FCγRIIIa. J. Proteome Res. 10: 3031-3039.
34. Ferrara, C., F. Stuart, P. Sondermann, P. Brünker, and P. Umaña. 2006. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281: 5032-5036.
35. Drescher, B., T. Witte, and R. E. Schmidt. 2003. Glycosylation of FcgammaRIII in N163 as mechanism of regulating receptor affinity. Immunology 110: 335-340.
36. Ravetch, J. V., and F. Nimmerjahn. 2008. Fc receptors. In Fundamental Immunology, 6th Ed. W. E. Paul, ed. Lippincott-Raven, Philadelphia, p. 684-705.
37. Tao, M. H., and S. L. Morrison. 1989. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143: 2595-2601.
38. Krapp, S., Y. Mimura, R. Jefferis, R. Huber, and P. Sondermann. 2003. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325: 979-989.
39. Pound, J. D., J. Lund, and R. Jefferis. 1993. Aglycosylated chimaeric human IgG3 can trigger the human phagocyte respiratory burst. Mol. Immunol. 30: 233-241.
40. Allhorn, M., and M. Collin. 2009. Sugar-free antibodies - the bacterial solution to autoimmunity? Ann. N. Y. Acad. Sci. 1173: 664-669.
41. Allhorn, M., A. I. Olin, F. Nimmerjahn, and M. Collin. 2008. Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis. PLoS ONE 3: e1413.
42. Collin, M., O. Shannon, and L. Björck. 2008. IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. Proc. Natl. Acad. Sci. USA 105: 4265-4270.
43. Baruah, K., T. A. Bowden, B. A. Krishna, R. A. Dwek, M. Crispin, and C. N. Scanlan. 2012. Selective deactivation of serum IgG: a general strategy for the enhancement of monoclonal antibody receptor interactions. J. Mol. Biol. 420: 1-7.
44. Matsumiya, S., Y. Yamaguchi, J. Saito, M. Nagano, H. Sasakawa, S. Otaki, M. Satoh, K. Shitara, and K. Kato. 2007. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J. Mol. Biol. 368: 767-779.
45. Voice, J. K., and P. J. Lachmann. 1997. Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. Eur. J. Immunol. 27: 2514-2523.
46. Barnes, N., A. L. Gavin, P. S. Tan, P. Mottram, F. Koentgen, and P. M. Hogarth. 2002. FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity 16: 379-389.
47. Baumann, U., J. Köhl, T. Tschernig, K. Schwerter-Strumpf, J. S. Verbeek, R. E. Schmidt, and J. E. Gessner. 2000. A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction. J. Immunol. 164: 1065-1070.
48. Ioan-Facsinay, A., S. J. de Kimpe, S. M. Hellwig, P. L. van Lent, F. M. Hofhuis, H. H. van Ojik, C. Sedlik, S. A. da Silveira, J. Gerber, Y. F. de Jong, et al. 2002. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16: 391-402.
49. Otten, M. A., G. J. van der Bij, S. J. Verbeek, F. Nimmerjahn, J. V. Ravetch, R. H. Beelen, J. G. van de Winkel, and M. van Egmond. 2008. Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J. Immunol. 181: 6829-6836.
50. Biburger, M., S. Aschermann, I. Schwab, A. Lux, H. Albert, H. Danzer, M. Woigk, D. Dudziak, and F. Nimmerjahn. 2011. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35: 932-944.
51. van der Poel, C. E., R. M. Spaapen, J. G. van de Winkel, and J. H. Leusen. 2011. Functional characteristics of the high affinity IgG receptor, FCγRI. J. Immunol. 186: 2699-2704.
52. Edberg, J. C., and R. P. Kimberly. 1997. Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding. J. Immunol. 159: 3849-3857.
53. Rönnelid, J., A. Tejde, L. Mathsson, K. Nilsson-Ekdahl, and B. Nilsson. 2003. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann. Rheum. Dis. 62: 37-42.
54. Garred, P., T. E. Michaelsen, and A. Aase. 1989. The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scand. J. Immunol. 30: 379-382.
55. Tao, M. H., S. M. Canfield, and S. L. Morrison. 1991. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J. Exp. Med. 173: 1025-1028.
56. Michaelsen, T. E., P. Garred, and A. Aase. 1991. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur. J. Immunol. 21: 11-16.
57. Lucisano Valim, Y. M., and P. J. Lachmann. 1991. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin. Exp. Immunol. 84: 1-8.